Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: results from the MAVERIC phase II trial
The MAVERIC trial demonstrated encouraging clinical benefit of everolimus in metastatic GEP-NEN and LCNEC (Ki-67 20%-55%) following first-line CT. Toxicity was consistent with the known safety profile of everolimus. This strategy was particularly effective in GEP-NEN patients and warrants further investigation. ClinicalTrials.gov identifier: NCT02687958 (https://clinicaltrials.gov/study/NCT02687958).
Authors
- Federica Cosso (ORCID: https://orcid.org/0000-0003-4851-9939)
- Massimo Milione (ORCID: https://orcid.org/0000-0002-1202-139X)
- Marco Brugia (ORCID: https://orcid.org/0000-0001-9389-5146)
- Francesco Di Costanzo (ORCID: https://orcid.org/0000-0002-6858-7827)
- Clotilde Sparano (ORCID: https://orcid.org/0000-0002-3766-4682)
- Riccardo Marconcini (ORCID: https://orcid.org/0000-0001-5120-911X)
- Fazio Nicola
- L. Messerini
- D. Rossini
- Luca Boni
- Elisa Giommoni
- Vito Amoroso
- F Scolari
- Lorenzo Antonuzzo
- Giulia Massaro
- Fabio Gelsomino
- Francesca Spada
Institutions
- University of Pisa (IT)
- University of Modena and Reggio Emilia (IT)
- Azienda Unita' Sanitaria Locale Di Modena (IT)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Azienda Socio Sanitaria Territoriale Lariana (IT)
- Ospedale Policlinico San Martino (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Azienda Ospedaliera Universitaria Pisana (IT)
- University of Florence (IT)
- European Institute of Oncology (IT)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1093/oncolo/oyaf432
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00